CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion

Falsetti, Lorenzo; Viticchi, Giovanna; Tarquinio, Nicola; Silvestrini, Mauro; Capeci, W.; Balloni, Andrea; Catozzo, Vania; Gentile, Adelina; Pellegrini, F.

doi:10.2459/jcm.0000000000000139

Cited by 15 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 2408 records were analyzed. After the first evaluation of titles and abstracts, 22 studies were screened and of these 15 were excluded with reasons as reported in Figure S1, while the remaining seven were analyzed as full‐paper . Thereafter the seven corresponding authors were contacted for joining the patient‐level meta‐analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Thereafter the seven corresponding authors were contacted for joining the patient‐level meta‐analysis. Three authors agreed to share data and were included in qualitative and quantitative analysis (Figure S1 and Table S1).…”

Section: Resultsmentioning

confidence: 99%

“…All these studies suggest a potential role of CHA 2 DS 2 ‐VASc as a marker of atrial electrical or mechanical remodeling, which could be responsible of AF recurrences after cardioversion. However, its predictive value for recurrences of AF is controversial …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis

Vitali

Serenelli

Airaksinen

et al. 2019

Clinical Cardiology

Self Cite

View full text Add to dashboard Cite

Background Despite progresses in the treatment of the thromboembolic risk related to atrial fibrillation (AF), the management of recurrences remains a challenge. Hypothesis To assess if congestive heart failure or left ventricular systolic dysfunction (CHA 2 DS 2 ‐VASc) score is predictive of early arrhythmia recurrence after AF cardioversion. Methods Systematic review and individual patient pooled meta‐analysis following Preferred Reporting Items for Systematic reviews and Meta‐Analyses guidelines. Inclusion criteria: observational trials in patients with AF undergoing cardioversion, available data on recurrence of AF and available data on CHA 2 DS 2 ‐VASc score. Clinical studies of interest were retrieved by PubMed, Cochrane Library, and Biomed Central. Seven authors were contacted for joining the patient level meta‐analysis, and three shared data regarding anthropometric measurements, risk factors, major comorbidities, and CHA 2 DS 2 ‐VASc score. The primary outcome was the recurrence of AF after cardioversion in patients free from antiarrhythmic prophylaxis. Univariate and multivariate logistic regression was performed. Results Overall, we collect data of 2889 patients: 61% were male, 50% with hypertension, 12% with diabetes, and 23% with history of ischemic heart disease. The median CHA2DS2‐VASc score was 2.. At the multivariate analysis, chronic kidney disease (odds ratio [OR] 1.94; 95% confidence interval [CI] 1.12‐3.27; P = 0.01), peripheral artery disease (OR 1.65; 95% CI 1.23‐2.19; P < 0,0001), previous use of beta blockers (OR 1.5; 95% CI 1.19‐1.88; P < 0.0001), and CHA2DS2‐VASc score > 2 (OR 1.37; 95% CI 1.1‐1.68; P = 0.002) were independent predictors of early recurrence of AF. Conclusions CHA2DS2‐VASc score predicts early recurrence of AF in the first 30 days after electrical or pharmacological cardioversion. Protocol registration PROSPERO (CRD42017075107).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis

Vitali

Serenelli

Airaksinen

et al. 2019

Clinical Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients undergoing electrical or pharmacological cardioversion, the CHA 2 DS 2 -VASc score emerged as a significant predictor of early recurrence of AF [10]. Similarly, in the “Leipzig Heart Center AF Ablation Registry,” the CHA 2 DS 2 -VASc score was associated with both early and late relapses of the arrhythmia [11].…”

Section: Discussionmentioning

confidence: 99%

Atrial fibrillation after electrical cardioversion in elderly patients: a role for arterial stiffness? Results from a preliminary study

et al. 2016

View full text Add to dashboard Cite

Background and aims Atrial fibrillation (AF) is the most frequent arrhythmia of the elderly, and electrical cardioversion (ECV) is a common procedure, although incidence of recurrences remains high. We evaluated the possible association between arterial stiffness (AS) and the persistence or recurrence of AF in elderly patients after ECV.MethodsWe enrolled all subjects undergoing ECV over a 9-month period. AS was evaluated with the cardio-ankle vascular index (CAVI). Patients were then visited at follow-up (on average at 6 months).ResultsThirty-one patients (age 78 ± 7 years; men 67.7 %; CHA2DS2-VASc 4.1 ± 1.6; AF length >2 months 51.6 %; CAVI 9.9 ± 1.6) underwent ECV. At follow-up, sinus rhythm was recorded in 16 (51.6 %) patients. At multivariate analysis, the presence of AF was directly associated with CHA2DS2-VASc score and CAVI. Amiodarone therapy reduced the risk of relapsed AF.ConclusionsIn elderly AF patients treated with ECV, AS at baseline seems to predict AF at follow-up.

show abstract

“…Falsetti et al suggested that the CHA 2 DS 2 VASc score could be useful in evaluating the risk of early recurrence of AF after electrical and pharmacological CV …”

Section: Discussionmentioning

confidence: 99%

CHA₂DS₂VASc score predicts unsuccessful electrical cardioversion in patients with persistent atrial fibrillation

Młodawska

Tomaszuk‐Kazberuk

Łopatowska

et al. 2017

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion

Abstract: Our preliminary results suggest that CHA2DS2-VASc score could be useful in evaluating the risk of early recurrence of atrial fibrillation after cardioversion. This information may have implications for disease monitoring and treatment strategies in clinical practice.

Cited by 15 publications

References 24 publications

CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis

CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis

Atrial fibrillation after electrical cardioversion in elderly patients: a role for arterial stiffness? Results from a preliminary study

CHA₂DS₂VASc score predicts unsuccessful electrical cardioversion in patients with persistent atrial fibrillation

Contact Info

Product

Resources

About

CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion

Abstract: Our preliminary results suggest that CHA2DS2-VASc score could be useful in evaluating the risk of early recurrence of atrial fibrillation after cardioversion. This information may have implications for disease monitoring and treatment strategies in clinical practice.

Cited by 15 publications

References 24 publications

CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis

CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis

Atrial fibrillation after electrical cardioversion in elderly patients: a role for arterial stiffness? Results from a preliminary study

CHA2DS2VASc score predicts unsuccessful electrical cardioversion in patients with persistent atrial fibrillation

Contact Info

Product

Resources

About

CHA₂DS₂VASc score predicts unsuccessful electrical cardioversion in patients with persistent atrial fibrillation